

Mona Yazdani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11015523/publications.pdf>

Version: 2024-02-01

11
papers

237
citations

1040056

9
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

298
citing authors

#	ARTICLE	IF	CITATIONS
1	Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy. <i>Scientific Reports</i> , 2021, 11, 14661.	3.3	19
2	Comparison of two routes of administration of a cationic liposome formulation for a prophylactic DC vaccination in a murine melanoma model. <i>International Immunopharmacology</i> , 2021, 98, 107833.	3.8	4
3	Ex vivo-generated dendritic cell-based vaccines in melanoma: the role of nanoparticulate delivery systems. <i>Immunotherapy</i> , 2020, 12, 333-349.	2.0	12
4	Vaccination with dendritic cells pulsed ex vivo with gp100 peptide-decorated liposomes enhances the efficacy of anti PD-1 therapy in a mouse model of melanoma. <i>Vaccine</i> , 2020, 38, 5665-5677.	3.8	15
5	Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy. <i>Iranian Journal of Basic Medical Sciences</i> , 2020, 23, 1065-1077.	1.0	7
6	Preparation of nanoliposomes containing HER2/neu (P5+435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer. <i>PLoS ONE</i> , 2020, 15, e0243550.	2.5	11
7	P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 664-672.	2.8	29
8	Preparation of nanoliposomes linked to HER2/neu-derived (P5) peptide containing MPL adjuvant as vaccine against breast cancer. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 1294-1303.	2.6	13
9	Stimulation of Tumor-Specific Immunity by p5 HER-2/neu Generated Peptide Encapsulated in Nano-liposomes with High Phase Transition Temperature Phospholipids. <i>Current Drug Delivery</i> , 2017, 14, 492-502.	1.6	11
10	P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer. <i>Cancer Letters</i> , 2014, 355, 54-60.	7.2	58
11	Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN. <i>Immunology Letters</i> , 2014, 162, 87-93.	2.5	58